---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-022390"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2022-09-14T23:59:59+00:00"
generated_at: "2026-06-23T09:36:38.159717+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma Q4 FY22 net income $1.5M, down 67% YoY; revenue falls 22%

## Summary
- Q4 revenue $13.3M, down 22.2% from $17.1M; operating income $0.4M vs $1.3M.
- Full fiscal year revenue $56.2M, down 11.6% from $63.6M; operating income $2.7M vs $5.8M.
- Full year diluted EPS $0.12 vs $0.25; net income $3.8M vs $8.0M.
- Co-CEOs cite normalization after pandemic-driven safety stock and demand as reasons for decline.

## SEC filing metadata
- accession: 0001437749-22-022390
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2022-09-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774922022390/0001437749-22-022390-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774922022390/inbp20220913_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-022390
- JSON: https://secwatch.observer/filing/0001437749-22-022390.json
- Plain text: https://secwatch.observer/filing/0001437749-22-022390.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.